Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid

van den Elsen, S. H. J., Akkerman, O. W., Wessels, M., Jongedijk, E. M., Ghimire, S., van der Werf, T. S., Bolhuis, M. S., Touw, D. J. & Alffenaar, J-W. C., 2020, In : European Respiratory Journal. 11 p.

Research output: Contribution to journalLetterAcademicpeer-review

ID: 129394743